Apremilast D5 (CC10004 D5; CC-10004 D5) is the penta-deuterated form of Apremilast (Otezla), which is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) and has been approved for treating psoriatic arthritis. It inhibits PDE4 with an IC50 of 74 nM.

纯度：≥98%

CAS：1258597-47-5